KERA: A Protein Regulator of Cell Cycle and Tissue Development

Target Name: KERA

NCBI ID: G11081

KERA

KERA: A Protein Regulator of Cell Cycle and Tissue Development

KERA (KTN) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the cell cycle, and is involved in the development and maintenance of normal cell structure and function. KERA has also been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, KERA has become a focus of interest in the scientific community, and is currently being targeted by researchers as a potential drug target or biomarker.

The KERA protein is composed of 19 different amino acids, and has a calculated molecular weight of 21 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is primarily localized to the cytoplasm. KERA is involved in the regulation of the cell cycle, and is thought to play a role in the development and maintenance of normal cell structure and function.

One of the key functions of KERA is its role in the regulation of the cell cycle. The cell cycle is the process by which a cell grows, replicates its DNA, and divides. KERA is involved in the regulation of the length and timing of cell cycles, and is thought to play a key role in the development of cancer.

In addition to its role in the cell cycle, KERA is also involved in the regulation of cell growth and differentiation. It is thought to play a role in the development and maintenance of normal tissues and organs, and is also involved in the regulation of cell shape and movement.

KERA has also been shown to be involved in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that KERA is often overexpressed in a variety of cancer types, and that inhibition of KERA has been shown to be effective in treating these diseases.

In addition to its potential as a drug target, KERA has also been shown to be a potential biomarker. The KERA gene is expressed in a variety of tissues throughout the body, and is often used as a target for diagnostic tests. For example, studies have shown that KERA is often overexpressed in a variety of neurodegenerative diseases, and that inhibition of KERA has been shown to be effective in treating these diseases.

Overall, KERA is a protein that is involved in a variety of important processes in the cell. Its role in the regulation of the cell cycle, cell growth and differentiation, and in the development and maintenance of normal tissues and organs makes it a potential drug target or biomarker. Further research is needed to fully understand the role of KERA in these processes, and to develop effective treatments for diseases in which it is involved.

Protein Name: Keratocan

Functions: May be important in developing and maintaining corneal transparency and for the structure of the stromal matrix

The "KERA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KERA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets